MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

Search

Sartorius Stedim Biotech.

Geschlossen

BrancheFinanzen

199.35 0.4

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

197.5

Max

200.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

75M

115M

Verkäufe

-6.7M

745M

KGV

Branchendurchschnitt

96.256

24.598

EPS

1.16

Dividendenrendite

0.34

Gewinnspanne

15.498

Angestellte

9,961

EBITDA

124M

256M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.68% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.34%

4.30%

Nächstes Ergebnis

22. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.3B

21B

Vorheriger Eröffnungskurs

198.95

Vorheriger Schlusskurs

199.35

Nachrichtenstimmung

By Acuity

37%

63%

128 / 540 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Sartorius Stedim Biotech. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Mai 2025, 22:52 UTC

Ergebnisse
Wichtige Markttreiber

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. Mai 2025, 20:37 UTC

Top News
Ergebnisse

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. Mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. Mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. Mai 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. Mai 2025, 22:46 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. Mai 2025, 22:46 UTC

Akquisitionen, Fusionen, Übernahmen

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. Mai 2025, 21:58 UTC

Ergebnisse

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. Mai 2025, 21:24 UTC

Ergebnisse

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. Mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. Mai 2025, 20:54 UTC

Market Talk
Ergebnisse

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. Mai 2025, 20:54 UTC

Ergebnisse

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. Mai 2025, 20:51 UTC

Ergebnisse

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Mai 2025, 20:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. Mai 2025, 20:50 UTC

Ergebnisse

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. Mai 2025, 20:47 UTC

Ergebnisse

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. Mai 2025, 20:37 UTC

Ergebnisse

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. Mai 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. Mai 2025, 20:25 UTC

Ergebnisse

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Sartorius Stedim Biotech. Prognose

Kursziel

By TipRanks

20.68% Vorteil

12-Monats-Prognose

Durchschnitt 239.13 EUR  20.68%

Hoch 250 EUR

Tief 210 EUR

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius Stedim Biotech. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

202.7 / 211.7Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

128 / 540 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.